Zealand Pharma A/S' obesity drug pipeline, including petrelintide, shows promise but faces high risks. Click to explore ZLDPF ...

Eli Lilly signs a global licensing deal with Rznomics to co-develop RNA-editing therapies for hearing loss, with potential deal value above $1.3 billion.

Rznomics Inc., a South Korea-based biopharmaceutical company specializing in RNA-based therapeutics, has entered into a ...

On May 16, Eli Lilly and Company (NYSE ... on a computer terminal with a patient in the background. The collaboration complements Lilly's existing genetic hearing loss pipeline, including AK ...

This partnership, which officials said has the potential to be the largest ever U.S. industry-academic agreement of its kind, ...

Eli Lilly is strengthening its position in genetic medicine for hearing loss through a new collaboration with South Korea-based biotech Rznomics. The agreement, centred on the development of RNA ...

INDIANAPOLIS and WEST LAFAYETTE, May 9, 2025 — Eli Lilly and Company (NYSE: LLY) and Purdue University announced today a significant expansion of their long-standing alliance, with Lilly’s planned ...

On May 16, Eli Lilly and ... while Lilly handles clinical development and commercialization using RNA editing, a reversible alternative to CRISPR. The collaboration complements Lilly’s existing ...

Eli Lilly and Co. and Purdue University announced today a significant expansion of their long-standing alliance, with Lilly’s planned investment of up to $250 million in the collaboration over ...